Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear (Acuity200OK)
Myopia
About this trial
This is an interventional treatment trial for Myopia focused on measuring orthokeratology, contact lens, Acuity, Overnight, myopia, myopic, astigmatism, astigmatic
Eligibility Criteria
Inclusion Criteria: Is age 7 or older with full legal capacity to volunteer or has parental or legal guardian written approval to volunteer; and has read, understood and signed the Informed Consent Form or Assent Form (for subjects 18 years and under); Is willing and able to follow participant instructions for product usage and meet the specified schedule of follow-up visits; Has naturally occurring refractive myopia from -0.75 to -6.00 diopters sphere (spectacle plane), with refractive astigmatism (spectacle plane) up to 1.75 DC-as determined by adjusted manifest refraction (phoropter or trial frame) with a 12.5 mm vertex distance. Has a best spectacle corrected visual acuity of 0.04 log MAR (20/20 -2) or better in each eye; Is free of eye disease and binocular vision problems (e.g., strabismus, amblyopia, oculomotor nerve palsies, corneal disease, etc.) that may affect vision or contact lens wear; Has normal healthy eyes with no evidence of lid infection or structural abnormality; a conjunctiva free of infection; a cornea clear and free of edema, visually or topographically significant scars, clinically significant staining, significant vascularization, infiltrates when examined by slit-lamp biomicroscopy; and no evidence of iritis or uveitis. Exclusion Criteria: Is pregnant, breast-feeding or intends to become pregnant over the course of the study. Is a potential pediatric subject that does not have the appropriate level of psychological maturity to comply with appropriate procedures needed for safe wear according to the investigator. Is a potential pediatric subject that is a ward of the State or any other agency, institution, or entity. Has a history of any of the following medical conditions: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine disorders (including, but not limited to active thyroid disorders and diabetes), lupus, and rheumatoid arthritis. NOTE: The presence of diabetes (either type 1 or 2), regardless of disease duration, severity or control, specifically excludes subjects from eligibility. Has a history of intraocular or corneal surgery (including cataract extraction and refractive surgery-such as Lasik), active ophthalmic disease or abnormality (including, but not limited to, blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization > 1mm from limbus), clinically significant lens opacity, clinical evidence of trauma (including scarring), or with evidence of glaucoma or propensity for narrow angle glaucoma as determined by gonioscopic examination in either eye. NOTE: This includes any subject with open angle glaucoma, regardless of medication regimen or control. Additionally, any subject with an IOP greater than 21 mm Hg at baseline is specifically excluded from eligibility. Has evidence of keratoconus, corneal irregularity, or abnormal video-keratography in either eye. Has a pupil size greater than 6.0 mm in photopic illumination as measured with pupil detection component of computer assisted video keratography. Has a corneal diameter of 10 mm or less; Has flat keratometry values flatter than 38.00D (8.88 mm), or steeper than 47.00D (7.16 mm); Takes medication that may cause dry eye or affect vision, corneal curvature, or healing (i.e., corticosteroids); Has an allergy to any ingredient in the study lens care solutions; Has significant ocular allergy, which would contraindicate solution use and/or "normal" contact lens wear; Is currently using or has a history of atropine use for myopia progression control Is a current wearer or previous wearer within the last 90 days of daily wear rigid gas permeable contact lenses, extended wear rigid gas permeable contact lenses, or orthokeratology contact lenses; Is participating in any other type of clinical or research study.
Sites / Locations
- Advanced Optometry of Mission Viejo
- Elsa Pao, O.D. Optometrist
- Pacific Rims Optometry
- Silicon Valley Eye Physicians
- Coan Eye Care
- Center for Ophthalmic and Vision Research, LLC
- Reed Eye Associates
- Bellaire Family Eye Care
- Innovative Eye Care
- Richard Lindsay and Associates
- Custom Eyecare Newcastle
- Eyeconic Optometry
- Rose Optometry
Arms of the Study
Arm 1
Other
Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
For the orthokeratology treatment the subjects will be instructed to wear the study lenses each night during the hours of sleep (for a minimum of 6 hours) and remove the lenses during the waking hours. The subject will be examined at 1 day, 1 week, 1 month, 3 months, 6 months, 9 months and 12 months after dispensing to evaluate the ocular physiology and the treatment effect. The target refractive error (sphere) will be plano for all subjects. All subjects enrolled at two of the investigational sites (targeted total of 40 subjects) will be evaluated for the stability of UCVA and manifest refraction throughout a single day on or following the 3 month, 6 month, or 9 month follow up visits. A post-treatment follow-up visit will be scheduled 1 month following discontinuation of the study lens. When it has been determined that no additional follow up visits are required, the subject will be discharged from the study.